Role of miR-483 in digestive tract cancers: from basic research to clinical value

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Digestive tract cancers (DTCs) are leading causes of cancer mortality worldwide.
• Despite advancements in treatment, DTCs remain a significant health concern.
• MicroRNAs (miRNAs) are small noncoding RNAs with roles in various diseases, including cancer.

Purpose of the Study:

• To review current findings on the role of microRNA-483 (miR-483) in digestive tract cancers.
• To discuss the potential of miR-483 as a novel biomarker for DTCs.
• To highlight challenges and future directions for clinical application of miR-483 in cancer therapy.

Main Methods:

• Literature review of recent profiling studies on miRNA expression in DTCs.
• Analysis of research investigating the association between miR-483 dysregulation and DTC phenotypes.
• Discussion of technical challenges and clinical translation hurdles.

Main Results:

• Aberrant expression of miR-483 is implicated in the tumor biology of various cancers, including DTCs.
• Profiling studies indicate miR-483's potential as a biomarker for digestive tract cancers.
• Significant diversities and technical difficulties exist in developing clinically relevant miR-483 signatures.

Conclusions:

• miR-483 is a promising candidate biomarker for digestive tract cancers.
• Overcoming technical challenges is crucial for the clinical utility of miR-483 signatures.
• Understanding miR-483's role may offer insights into molecularly targeted cancer treatments.